Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens

BACKGROUND: Front‐line platinum‐base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front‐line regimens: cisplatin, doxorubicin, and cyclophospha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Wei‐Li, Lin, Chia‐Chi, Hsu, Feng‐Ming, Lee, Jang‐Ming, Chen, Jin‐Shing, Huang, Yen‐Lin, Chang, Yih‐Leong, Chang, Chin‐Hao, Yang, James Chih‐Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487882/
https://www.ncbi.nlm.nih.gov/pubmed/35348307
http://dx.doi.org/10.1002/cam4.4711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487882/
https://www.ncbi.nlm.nih.gov/pubmed/35348307
http://dx.doi.org/10.1002/cam4.4711

Ejemplares similares